Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19214778 | METHOD OF TREATING CANCER USING A ZrO2@CaSiO3@g-C3N4 NANOCOMPOSITE MATERIAL | May 2025 | July 2025 | Allow | 2 | 0 | 0 | No | No |
| 19202501 | 3-(Hydroxy)-Pyridin-4(1H)-One Compounds and Methods of Making and Using the Same | May 2025 | September 2025 | Allow | 4 | 1 | 0 | No | No |
| 19174523 | ANTICANCER AGENTS COMPRISING A g-C3N4@CuO/MgAl2O4 NANOHYBRID | April 2025 | July 2025 | Allow | 3 | 1 | 0 | No | No |
| 19064093 | INHIBITION OF CANCER CELL VIABILITY | February 2025 | April 2025 | Allow | 2 | 1 | 0 | No | No |
| 18976761 | COMPOSITIONS FOR TARGETED DELIVERY OF THERAPEUTIC AGENTS AND METHODS FOR THE SYNTHESIS AND USE THEREOF | December 2024 | April 2025 | Allow | 4 | 1 | 0 | Yes | No |
| 18952635 | COATED ZEOLITIC IMIDAZOLATE FRAMEWORK (ZIF-8) AS AN EFFICIENT CARRIER FOR THE CYCLOHEPTYLAMINE HYDROCHLORIDE FOR THE TREATMENT OF DIABETES | November 2024 | September 2025 | Allow | 10 | 2 | 0 | No | No |
| 18948050 | CRYSTALLINE FORM OF TRIETHYLENETETRAMINE TETRAHYDROCHLORIDE AND ITS PHARMACEUTICAL USE | November 2024 | March 2025 | Allow | 4 | 1 | 0 | No | No |
| 18923620 | ANTI-AGING PREPARATION FOR SKIN AND APPLICATION THEREOF | October 2024 | January 2025 | Allow | 3 | 1 | 0 | No | No |
| 18668526 | METHOD TO SELECTIVELY PRODUCE BENZALANILINE FROM A SCHIFF-BASE REACTION INVOLVING ANILINE AND BENZALDEHYDE | May 2024 | February 2025 | Allow | 9 | 2 | 0 | No | No |
| 18669214 | LIPIDS AND LIPID NANOPARTICLE FORMULATIONS | May 2024 | October 2024 | Allow | 5 | 0 | 1 | No | No |
| 18659997 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR SELECTIVELY INHIBITING ß-GLUCURONIDASES AND ALLEVIATING SIDE EFFECTS ASSOCIATED WITH DRUG TREATMENT INDUCED DIARRHEA | May 2024 | November 2025 | Abandon | 18 | 0 | 1 | No | No |
| 18648426 | TREATMENT OF NEUROFIBROMATOSIS TYPE 1 (NF1) ASSOCIATED PLEXIFORM NEUROFIBROMAS (PN) IN PEDIATRIC PATIENTS WITH MIRDAMETINIB | April 2024 | March 2025 | Allow | 10 | 2 | 0 | No | No |
| 18647511 | METHODS AND COMPOSITIONS FOR TREATING CANCER | April 2024 | April 2025 | Allow | 12 | 2 | 0 | Yes | No |
| 18637083 | INDOLE AND BENZIMIDAZOLE DERIVATIVES AS DUAL 5-HT 2A AND 5-HT6 RECEPTOR ANTAGONISTS | April 2024 | April 2025 | Allow | 12 | 1 | 0 | No | No |
| 18632908 | PHOSPHORAMIDATES FOR THE TREATMENT OF HEPATITIS B VIRUS | April 2024 | December 2025 | Allow | 20 | 2 | 1 | No | No |
| 18630283 | METHODS OF TREATING MALIGNANT LYMPHOPROLIFERATIVE DISORDERS | April 2024 | November 2025 | Abandon | 19 | 1 | 0 | No | No |
| 18624670 | TREATMENTS WITH NIROGACESTAT | April 2024 | October 2024 | Allow | 6 | 2 | 0 | No | No |
| 18618110 | SUBSTITUTED NAPHTHYL P38ALPHA MITOGEN-ACTIVATED PROTEIN KINASE INHIBITORS | March 2024 | February 2025 | Allow | 11 | 2 | 1 | No | No |
| 18617058 | LIPID COMPOUNDS AND LIPID NANOPARTICLE COMPOSITIONS | March 2024 | December 2025 | Allow | 21 | 1 | 1 | No | No |
| 18594898 | MONOHYDRATE AND CRYSTALLINE FORMS OF 6-[(3S,4S)-4-METHYL-1-(PYRIMIDIN-2-YLMETHYL)PYRROLIDIN-3-YL]-3-TETRAHYDROPYRAN-4-YL-7H-IMIDAZO[1,5-A]PYRAZIN-8-ONE | March 2024 | July 2025 | Allow | 16 | 2 | 0 | No | No |
| 18581307 | SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | February 2024 | April 2025 | Allow | 14 | 1 | 1 | No | No |
| 18439677 | FABRICATION OF NOVEL NANO-SIZED [4{3,4-BIS-[(5-BROMO-2-HYDROXY-BENZYLIDENE)-AMINO]-PHENYL}-PHENYL-METHANONE] RU(III) COMPLEX FOR PHARMACEUTICAL APPLICATIONS | February 2024 | August 2024 | Allow | 6 | 1 | 0 | No | No |
| 18417750 | COMPOSITIONS COMPRISING AN UROLITHIN COMPOUND | January 2024 | January 2025 | Allow | 12 | 1 | 0 | No | No |
| 18414185 | TREATMENTS WITH NIROGACESTAT | January 2024 | August 2024 | Allow | 7 | 1 | 0 | No | No |
| 18399875 | FOAM TREATMENT METHOD FOR BACTERIA | December 2023 | January 2026 | Allow | 25 | 2 | 0 | No | No |
| 18570072 | ULTRASOUND-RESPONSIVE LIPOSOME NANOPARTICLES AND PREPARATION METHOD AND USE THEREOF | December 2023 | December 2025 | Allow | 24 | 1 | 0 | No | No |
| 18538562 | METHODS OF INACTIVATION OF VIRUSES USING N-METHYLGLUCAMIDE AND ITS DERIVATIVES | December 2023 | March 2025 | Abandon | 15 | 1 | 0 | No | No |
| 18567972 | Treatment for Down Syndrome-Related Accelerated Aging | December 2023 | March 2026 | Allow | 27 | 1 | 0 | No | No |
| 18565865 | MEANS AND METHODS FOR IMPROVING ANTI-TUMORAL EFFICACY OF TRANSMEMBRANE CHANNEL PROTEIN BLOCKERS | November 2023 | February 2026 | Allow | 26 | 1 | 0 | No | No |
| 18289738 | A PLURALITY OF TASQUINIMOD PARTICLES AND USE THEREOF | November 2023 | September 2025 | Allow | 23 | 0 | 0 | No | No |
| 18386906 | CRYSTALLINE FORM OF TRIETHYLENETETRAMINE TETRAHYDROCHLORIDE AND ITS PHARMACEUTICAL USE | November 2023 | March 2025 | Allow | 16 | 2 | 0 | No | No |
| 18498542 | ANTI-ANDROGENS FOR THE TREATMENT OF METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER | October 2023 | January 2025 | Allow | 15 | 2 | 0 | No | No |
| 18287446 | IMMUNOSTIMULATORY TOLL-LIKE RECEPTOR AGONIST-NANOPARTICLE FOR CANCER IMMUNOTHERAPY | October 2023 | March 2026 | Allow | 29 | 2 | 0 | No | No |
| 18470182 | COMPOSITIONS AND METHODS FOR TREATING, PREVENTING OR REVERSING AGE ASSOCIATED INFLAMMATION AND DISORDERS | September 2023 | November 2024 | Allow | 14 | 2 | 0 | No | No |
| 18464965 | METHODS OF TREATING CHRONIC INFLAMMATORY DISEASES | September 2023 | December 2025 | Allow | 27 | 2 | 0 | No | No |
| 18460047 | INHIBITING ATAXIA TELANGIECTASIA AND RAD3-RELATED PROTEIN (ATR) | September 2023 | December 2024 | Abandon | 15 | 1 | 0 | No | No |
| 18238905 | Series of Skin-Whitening (Lightening) Compounds | August 2023 | October 2024 | Allow | 13 | 1 | 0 | No | No |
| 18237140 | BETA-LACTAM DERIVATIVES FOR THE TREATMENT OF DISEASES | August 2023 | August 2024 | Allow | 12 | 1 | 0 | No | No |
| 18277652 | NITRIC OXIDE-SENSITIVE HYDROGEL | August 2023 | November 2025 | Allow | 27 | 1 | 0 | No | No |
| 18362789 | CATIONIC LIPIDS AND TRANSFECTION METHODS | July 2023 | April 2025 | Allow | 21 | 2 | 0 | No | No |
| 18358998 | SUBSTITUTED PYRIDINES AS DNMT1 INHIBITORS | July 2023 | June 2024 | Allow | 11 | 1 | 0 | No | No |
| 18215257 | MINOCYCLINE COMPOUNDS FOR BIODEFENSE | June 2023 | January 2025 | Abandon | 18 | 1 | 0 | No | No |
| 18340978 | SMALL MOLECULE INHIBITORS OF UBIQUITIN SPECIFIC PROTEASE 1 (USP1) AND USES THEREOF | June 2023 | November 2025 | Allow | 28 | 1 | 1 | No | No |
| 18315404 | METHODS OF TREATING HEMATOLOGICAL MALIGNANCIES USING 2-(2,6-DIOXOPIPERIDIN-3-YL)-4-((2-FLUORO-4-((3-MORPHOLINOAZETIDIN-1-YL)METHYL)BENZYL)AMINO)ISOINDOLINE-1,3-DION | May 2023 | August 2024 | Allow | 15 | 1 | 0 | No | No |
| 18315041 | CAPSID INHIBITORS FOR THE PREVENTION OF HIV | May 2023 | October 2024 | Abandon | 17 | 1 | 0 | No | No |
| 18314442 | METHODS OF TREATING CHRONIC INFLAMMATORY DISEASES | May 2023 | July 2024 | Allow | 14 | 1 | 0 | No | No |
| 18297974 | 3-(Hydroxy)-Pyridin-4(1H)-One Compounds and Methods of Making and Using the Same | April 2023 | February 2025 | Allow | 22 | 2 | 0 | Yes | No |
| 18297134 | CARBOXYLIC ACID AROMATIC AMIDES AS ANTAGONISTS OF BRADYKININ B1 RECEPTOR | April 2023 | October 2024 | Allow | 19 | 2 | 0 | No | No |
| 18188706 | METHOD FOR TREATING CANCER | March 2023 | January 2025 | Abandon | 22 | 1 | 0 | No | No |
| 18124959 | GLUCOCORTICOID RECEPTOR MODULATORS TO TREAT PANCREATIC CANCER | March 2023 | April 2025 | Allow | 25 | 1 | 0 | No | No |
| 18117075 | METHODS OF TREATING CANCER WITH AN FGFR INHIBITOR | March 2023 | May 2024 | Allow | 15 | 2 | 0 | No | No |
| 18103410 | Crystalline Forms of (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methylpropyl)-phenol hydrochloride | January 2023 | January 2026 | Abandon | 35 | 1 | 0 | No | No |
| 18007166 | OXA-AZASPIRO DERIVATIVE, AND PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | January 2023 | February 2026 | Abandon | 36 | 1 | 0 | No | No |
| 18018079 | COMPOSITION FOR TREATING KCA3.1 CHANNEL-MEDIATED DISEASES COMPRISING PHENYLALKYL CARBAMATE COMPOUND | January 2023 | February 2026 | Abandon | 36 | 1 | 0 | No | No |
| 18006261 | COMPOUNDS USEFUL AS FACTOR XIA INHIBITORS | January 2023 | October 2025 | Allow | 33 | 1 | 0 | No | No |
| 17999557 | TRIAZOLONE COMPOUND | January 2023 | December 2025 | Allow | 37 | 1 | 1 | Yes | No |
| 18016819 | COMPOSITIONS AND METHODS FOR TREATING LUNG INFLAMMATION | January 2023 | February 2026 | Abandon | 37 | 1 | 0 | No | No |
| 18005754 | HYDROCARBYL-MODIFIED METHYLALUMINOXANE COCATALYSTS FOR BIS-PHENYLPHENOXY METAL-LIGAND COMPLEXES | January 2023 | December 2025 | Allow | 35 | 1 | 0 | Yes | No |
| 18005159 | CRYSTALLINE FORM OF HYDROCHLORIDE SALT OF QUINOLINE DERIVATIVE | January 2023 | October 2025 | Allow | 33 | 1 | 0 | No | No |
| 18015691 | KRAS G12D INHIBITORS | January 2023 | March 2026 | Allow | 38 | 3 | 0 | No | No |
| 18093599 | TREATMENT OF CANCER, INFLAMMATORY DISEASES AND AUTOIMMUNE DISEASES | January 2023 | December 2025 | Allow | 36 | 2 | 0 | No | No |
| 18014143 | HETEROCYCLIC COMPOUND AND USE THEREOF | December 2022 | February 2026 | Allow | 38 | 1 | 1 | No | No |
| 18067975 | NUCLEIC ACID-POLYPEPTIDE COMPOSITIONS AND USES THEREOF | December 2022 | March 2025 | Allow | 27 | 0 | 1 | No | No |
| 18010604 | METHOD FOR PROMOTING COLLAGEN PRODUCTION | December 2022 | January 2026 | Allow | 37 | 2 | 0 | No | No |
| 18008873 | SUBSTITUTED ISOQUINOLINYLMETHYL AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME | December 2022 | December 2025 | Abandon | 36 | 0 | 1 | No | No |
| 17999723 | PREVENTION OF MCPD FORMATION BY HIGH TEMPERATURE WASHING | November 2022 | October 2025 | Allow | 35 | 1 | 0 | No | No |
| 18057724 | ANTIBACTERIAL HYDROPHILIC COMPOUND | November 2022 | June 2025 | Abandon | 31 | 1 | 1 | No | No |
| 17998957 | MACROCYCLIC 7-PYRAZOL-5-YL-INDOLE DERIVATIVES AS INHIBITORS OF MCL-1 | November 2022 | December 2025 | Abandon | 36 | 1 | 0 | No | No |
| 17924601 | Methods of Treating Bone Marrow Failure Syndromes and Compositions for Use in the Same | November 2022 | July 2025 | Allow | 32 | 1 | 0 | No | No |
| 17778298 | CARBALYSOPHOSPHATIDIC ACID | November 2022 | May 2025 | Allow | 36 | 0 | 0 | No | No |
| 17924261 | METHOD FOR PREPARING CHIRAL 4-ARYL-ß-AMINO ACID DERIVATIVE | November 2022 | September 2025 | Allow | 35 | 1 | 0 | No | No |
| 17921939 | HETEROCYCLIC COMPOUNDS AS BET INHIBITORS | October 2022 | November 2025 | Abandon | 37 | 0 | 1 | No | No |
| 17961437 | SMALL MOLECULES FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND CANCER | October 2022 | February 2026 | Allow | 40 | 2 | 1 | No | No |
| 17937599 | METHODS AND COMPOSITIONS FOR INDUCING FERROPTOSIS IN VIVO | October 2022 | March 2025 | Abandon | 29 | 1 | 1 | No | No |
| 17995002 | CO-ADMINISTRATION OF MIRDAMETINIB AND LIFIRAFENIB FOR USE IN TREATING CANCERS | September 2022 | May 2025 | Allow | 32 | 0 | 0 | No | No |
| 17915101 | Crystal Form Of Thiofuran Pyridazine Compound, Preparation Method Therefor And Application Thereof | September 2022 | February 2026 | Abandon | 41 | 2 | 0 | No | No |
| 17907151 | PROCESS SULFONATION OF AMINOETHYLENE SULFONIC ESTER WITH CARBON DIOXIDE ADDITION TO PRODUCE TAURINE | September 2022 | September 2025 | Allow | 36 | 1 | 0 | No | No |
| 17946101 | Benzisoxazole Sulfonamide Derivatives | September 2022 | February 2024 | Allow | 17 | 1 | 0 | No | No |
| 17911788 | PROCESS FOR CONVERTING BIOSOURCED TRIGLYCERIDES INTO A SINGLE-PHASE COMPOSITION CONTAINING FATTY ACID ESTER AND RELATED USES AS BIOFUEL OR LUBRICANT | September 2022 | September 2025 | Allow | 36 | 1 | 0 | No | No |
| 17905953 | Novel 3,5-Diaminobenzoic Acid Compound, and PIN1 Inhibitor and Therapeutic Agent for Inflammatory Diseases Using Same | September 2022 | September 2025 | Allow | 37 | 1 | 0 | No | No |
| 17887480 | Series of Compounds for Treatment of Skin Diseases and Other Conditions | August 2022 | March 2025 | Allow | 31 | 2 | 1 | No | No |
| 17882905 | COMPOSITIONS AND METHODS OF USE OF BETA-HYDROXY-BETA-METHYLBUTYRATE (HMB) FOR MODULATING AUTOPHAGY AND LIPOPHAGY | August 2022 | September 2024 | Allow | 26 | 2 | 0 | No | No |
| 17877485 | PARTICLE-FORM HYBRID-SCALE FIBER MATRIX | July 2022 | June 2023 | Abandon | 10 | 1 | 1 | No | No |
| 17809179 | DISSOLVED C60 AND METHOD OF PRODUCING DISSOLVED C60 | June 2022 | August 2025 | Allow | 38 | 1 | 0 | No | No |
| 17757514 | COMBINATIONS | June 2022 | October 2025 | Abandon | 40 | 1 | 0 | No | No |
| 17751540 | BRANCHED MULTI-FUNCTIONAL MACROMONOMERS AND RELATED POLYMERS AND USES THEREOF | May 2022 | August 2024 | Allow | 26 | 1 | 0 | No | No |
| 17750262 | COMPOSITIONS COMPRISING 15-HEPE AND METHODS OF USING THE SAME | May 2022 | January 2024 | Allow | 20 | 2 | 0 | No | No |
| 17775402 | LEFT-HANDED BICYCLIC MORPHOLINE AND SALT THEREOF, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION, AND USE | May 2022 | January 2026 | Allow | 45 | 2 | 0 | Yes | No |
| 17775242 | TREATING LIVER DISORDERS | May 2022 | December 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17774583 | CANCER TREATMENTS TARGETING CANCER STEM CELLS | May 2022 | December 2025 | Allow | 43 | 1 | 1 | No | No |
| 17772264 | LIVER TARGETING DRUG, PHARMACEUTICAL COMPOSITION AND USE THEREOF | April 2022 | August 2025 | Allow | 40 | 1 | 1 | No | No |
| 17770515 | METHODS OF TREATING, AMELIORATING, AND/OR PREVENTING CANCER USING PYRVINIUM COMPOSITIONS | April 2022 | July 2025 | Allow | 38 | 1 | 0 | No | No |
| 17714268 | SOLID STATE FORMS OF RELUGOLIX | April 2022 | June 2025 | Allow | 39 | 1 | 0 | No | No |
| 17762713 | CRYSTALLINE FORM OF A MULTI-TYROSINE KINASE INHIBITOR, METHOD OF PREPARATION, AND USE THEREOF | March 2022 | July 2025 | Allow | 40 | 1 | 0 | No | No |
| 17695767 | CXCL10 Inhibitors | March 2022 | November 2024 | Abandon | 32 | 2 | 1 | No | No |
| 17637450 | BILE ACID DERIVATIVE, COMPOSITION AND APPLICATION THEREOF | February 2022 | July 2025 | Allow | 41 | 1 | 1 | No | No |
| 17636276 | COMPOUNDS AND COMPOSITIONS FOR TREATING KIDNEY DISEASE | February 2022 | August 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17670078 | ALCOHOL-RESISTANT DRUG FORMULATIONS | February 2022 | June 2025 | Allow | 40 | 2 | 1 | No | No |
| 17630124 | PYRROLOPYRAZOLE DERIVATIVES, PREPARATION METHOD THEREOF AND APPLICATION THEREOF IN MEDICINE | January 2022 | April 2025 | Allow | 39 | 1 | 0 | No | No |
| 17628017 | CARBAMATE-SUBSTITUTED STYRYL SULFONE COMPOUNDS, PREPARATION METHOD AND USE THEREOF | January 2022 | May 2025 | Allow | 40 | 1 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner DAVIS, BRIAN J.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 60.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the top 25% across the USPTO, indicating that filing appeals is particularly effective here. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner DAVIS, BRIAN J works in Art Unit 1614 and has examined 243 patent applications in our dataset. With an allowance rate of 94.7%, this examiner allows applications at a higher rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 20 months.
Examiner DAVIS, BRIAN J's allowance rate of 94.7% places them in the 83% percentile among all USPTO examiners. This examiner is more likely to allow applications than most examiners at the USPTO.
On average, applications examined by DAVIS, BRIAN J receive 1.33 office actions before reaching final disposition. This places the examiner in the 19% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by DAVIS, BRIAN J is 20 months. This places the examiner in the 92% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.
Conducting an examiner interview provides a +6.2% benefit to allowance rate for applications examined by DAVIS, BRIAN J. This interview benefit is in the 33% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 34.2% of applications are subsequently allowed. This success rate is in the 75% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 68.9% of cases where such amendments are filed. This entry rate is in the 91% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 86% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 36.0% are granted (fully or in part). This grant rate is in the 24% percentile among all examiners. Strategic Note: Petitions are rarely granted regarding this examiner's actions compared to other examiners. Ensure you have a strong procedural basis before filing a petition, as the Technology Center Director typically upholds this examiner's decisions.
Examiner's Amendments: This examiner makes examiner's amendments in 17.3% of allowed cases (in the 97% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 5.2% of allowed cases (in the 81% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.